Fesarius Therapeutics announced the close of an oversubscribed $20 million Series A financing led by Jefferson Life Sciences, with participation from Johnson & Johnson Innovation, NY Ventures and the American Society of Plastic Surgeons.
The company plans to use the funding to expand its commercial infrastructure, pursue breakthrough device designation and advance clinical trials for DermiSphere™ hDRT.
